Developer docs
API playgroundTry for free, no card

Search company profiles

Taro Pharmaceutical Industries

Full company profile

uuid000apsu

Namestring
Taro Pharmaceutical Industries
Legal namestring
Taro Pharmaceutical Industries Ltd.
Websiteurl
taro.co.il
Company typeenum
Private
Founded yearint
1950
Descriptiontext

Taro Pharmaceutical Industries Ltd. is an Israel-headquartered multinational pharmaceutical company founded in 1950 as a collaboration between Israeli pharmacists and American physicians. The company develops, manufactures, and markets a broad portfolio of prescription (Rx) medications, over-the-counter (OTC) products, and cosmetics across therapeutic areas including pain and inflammation, dermatology, cardiovascular, neurology and psychiatry, oncology, ophthalmology, gastroenterology, and endocrinology. Taro's core technical asset is vertical integration: its Chemistry Division in Haifa Bay synthesizes active pharmaceutical ingredients (APIs) across seven production lines, while its Pharma Division manufactures finished dosage forms through dedicated cells for dry-mix, granulation, liquids and foams, and semi-solids. R&D centers in Haifa, Brampton (Canada), and Hawthorne, NY focus on formulation, analytical development, and synthetic organic chemistry, supporting bioequivalence and clinical endpoint studies from pre-clinical through Phase IV.

The company sells its products through four wholly-owned regional subsidiaries — Taro USA, Taro Canada, Taro Israel, and Taro International — distributing Rx, OTC, and cosmetic products through pharmaceutical supply chains across North America, Central America, East Asia, Europe, Australia, and Israel. The revenue model is product sales across three categories (Rx, OTC, cosmetics) plus API manufacturing, with horizontal segmentation across therapeutic areas and persona-level targeting of healthcare professionals and end patients. Pricing is not publicly disclosed. Taro's competitive positioning rests on cGMP compliance certified by the FDA, UK MHRA, and Israeli Ministry of Health; IP-protected branded dermatological products; and leadership in US generic dermatology by 2016. The company was acquired by Sun Pharmaceuticals in 2010, completed an NYSE IPO in 2012 (the same year it surpassed $1B in gross sales), acquired Alchemee in 2022 to expand branded dermatology, and became a private wholly-owned subsidiary of Sun Pharma on June 24, 2024.

Short descriptiontext

Taro Pharmaceutical Industries is an Israel-based multinational generic and specialty pharmaceutical manufacturer developing, producing, and distributing Rx, OTC, and cosmetic products across multiple therapeutic areas through regional subsidiaries, now operating as a wholly-owned subsidiary of Sun Pharma since June 2024.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersHaifa, Israel
HQ citystring
Haifa
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, prescription medications, topical dermatology, active pharmaceutical ingredients, finished dosage forms
Industry1 code
PRIMARYHLAIACAL
Dermatology Specialty Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Generic Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Prescription (Rx) Pharmaceutical Products
TypeOne Time License
Description

Revenue from prescription-only medications developed and manufactured by Taro, covering therapeutic areas including pain, dermatology, digestive system, nervous system, cardiology, and more.

2Over-the-Counter (OTC) Products
TypeOne Time License
Description

Revenue from non-prescription products available directly to consumers, including topical formulations and other treatments.

3Cosmetic Products
TypeOne Time License
Description

Revenue from topical cosmetic products including creams, ointments, lotions, gels, and foams.

4Active Pharmaceutical Ingredients (API)
TypeOne Time License
Description

Manufacturing and sale of active pharmaceutical ingredients used in medications for skin, cardiovascular, pain, and central nervous system conditions.

taro.co.il
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Supply Chain, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Taro Pharmaceutical Industries develops, manufactures, and markets a broad portfolio of prescription (Rx), over-the-counter (OTC), and cosmetic pharmaceutical products across therapeutic areas including pain, dermatology, digestive system, nervous system, cardiology, oncology, and ophthalmology. The company is vertically integrated, synthesizing its own active pharmaceutical ingredients (APIs) and producing finished dosage forms in tablets, capsules, creams, ointments, gels, foams, solutions, and injectables. Taro operates R&D centers in Israel, Canada, and the United States, and is recognized as the leading generic dermatological company in the US market.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Taro Pharmaceutical Industries is a multinational pharmaceutical company that develops, manufactures, and markets a broad portfolio of prescription (Rx) medications across multiple therapeutic areas including pain/inflammation, dermatology, cardiovascular, neurology/psychiatry, oncology, ophthalmology, and gastroenterology. The company offers products in various delivery forms including tablets, capsules, films, solutions, suspensions, creams, ointments, gels, foams, and injectables. Taro operates through two main divisions: the Pharma Division (manufacturing finished dosage forms including dry-mix, granulation, liquids/foams, and semi-solids production cells) and the Chemistry Division (manufacturing active pharmaceutical ingredients). R&D centers in Haifa (Israel), Brampton (Canada), and Hawthorne (NY, USA) focus on generic and branded products spanning oral solid-dose immediate and modified-release formulations, liquids, and dermatological topical formulations including creams, ointments, lotions, gels, and foams. The company is a leader in topical generic products and has developed extensive over-the-counter (OTC) offerings alongside its Rx portfolio.

Product and service42 records
1Aquimod
CategoryRx Dermatology
2Brexin
CategoryRx Anti-inflammatory
3Capecitabine Taro
CategoryRx Oncology
4Cinacalcet Taro
CategoryRx Anesthesia
5Coumadin
CategoryRx Cardiology
6Curatane
CategoryRx Dermatology
7Dermacombin
CategoryRx Dermatology
8Diprofol
CategoryRx Anesthesia
9Dorzolamide Timolol Taro
CategoryRx Ophthalmology
10Dutasteride Taro
CategoryRx Dermatology
11Entumin
CategoryRx Neurology/Psychiatry
12Estelle 35
CategoryRx Women's Health
13Etopan
CategoryRx Pain/Inflammation
14Etopan XL
CategoryRx Pain/Inflammation
15Etoricoxib Taro
CategoryRx Anti-inflammatory
16Lataro
CategoryRx Ophthalmology
17Lataro-Tim
CategoryRx Ophthalmology
18Lozapine
CategoryRx Neurology/Psychiatry
19Mercaptizol
CategoryRx Endocrinology
20Meroken
CategoryRx Gastroenterology
21Nystatin Ready Mix
CategoryRx Oral Health
22Odomzo
CategoryRx Oncology/Dermatology
23Otomycin
CategoryRx Otology
24Oxacatin
CategoryRx Respiratory
25Paracetamol Taro IV
CategoryRx Pain/Inflammation
26Partane
CategoryRx Neurology/Psychiatry
27Percocet
CategoryRx Pain Management
28Perphenan
CategoryRx Neurology/Psychiatry
29Pregabalin Taro
CategoryRx Neurology/Psychiatry
30Profex
CategoryRx Cardiology
31Promnix
CategoryRx Urology
32Rokacet Plus
CategoryRx Pain Relief
33Sevelamer Taro
CategoryRx Renal Care
34Sterocort
CategoryRx Anti-inflammatory
35Taroclindin
CategoryRx Dermatology
36Teril
CategoryRx Neurology/Psychiatry
37Uramox
CategoryRx Travel Medicine
38Zindaclin 1% Gel
CategoryRx Dermatology
39Zoledronic Acid Taro
CategoryRx Oncology
40Active Pharmaceutical Ingredients (API)
CategoryAPI Manufacturing
41Over-the-Counter (OTC) Pharmaceutical Products
CategoryOTC Products
42Cosmetic Products
CategoryCosmetics
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Sun Pharmaceutical USA
Strategic tierMinorTypeOthers
Description

Affiliate company of Sun Pharma serving the US market.

2Sun Pharmaceutical Europe
Strategic tierMinorTypeOthers
Description

Affiliate company of Sun Pharma serving the European market.

Strategic tierMinorTypeOthers
Description

Affiliate company under the Sun Pharma umbrella.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

India-based global generic and specialty pharmaceutical company with a notable dermatology franchise. Comparable to Taro on integrated API-to-dosage manufacturing and dermatology emphasis.

TypeDirect peer
Description

US-based generic and OTC pharmaceutical manufacturer with strong consumer self-care and dermatology franchises. Comparable to Taro on the OTC + Rx + dermatology + multi-region distribution model.

3Sandoz
TypeDirect peer
Description

Global generic pharmaceuticals business spun off from Novartis, offering broad Rx generics including dermatology, anti-infectives, and oncology. Comparable to Taro as a vertically capable generic manufacturer serving regulated markets.

TypeDirect peer
Description

Indian-headquartered global generic pharmaceutical manufacturer with broad therapeutic coverage including dermatology. Comparable to Taro as a vertically integrated generic player supplying regulated markets.

TypeDirect peer
Description

Specialty pharmaceutical company with significant generic dermatology and women's health franchises. Comparable to Taro on US-focused generic dermatology leadership and topical formulation capabilities.

TypeDirect peer
Description

Israel-headquartered global generic pharmaceutical leader with a meaningful dermatology franchise. Taro is most directly comparable to Teva as both are Israeli generic pharma companies with multi-therapeutic portfolios and US market exposure.

TypeEmerging player
Description

Dermatology-focused pharmaceutical and skincare company with strong prescription and consumer brands. Comparable to Taro on the dermatology focus, though more skewed toward branded aesthetics and skin care.

TypeDirect peer
Description

European dermatology-focused specialty pharmaceutical company. Directly comparable to Taro on the dermatology specialty positioning, with overlapping therapeutic focus on skin conditions.

TypeDirect peer
Description

Global generics and specialty pharmaceutical company formed from Mylan/Upjohn merger. Comparable to Taro on multi-therapeutic generic portfolio, established dermatology position, and global supply chain scale.

TypeDirect peer
Description

Indian generic pharmaceutical major with US-focused operations across multiple therapeutic areas. Comparable to Taro on US generic commercialization, multi-therapeutic portfolio, and API integration.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Taro Pharmaceutical Industries

Generic Pharmaceuticalstaro.co.il

Taro Pharmaceutical Industries is an Israel-based multinational generic and specialty pharmaceutical manufacturer developing, producing, and distributing Rx, OTC, and cosmetic products across multiple therapeutic areas through regional subsidiaries, now operating as a wholly-owned subsidiary of Sun Pharma since June 2024.

What Taro Pharmaceutical Industries does

Taro Pharmaceutical Industries Ltd. is an Israel-headquartered multinational pharmaceutical company founded in 1950 as a collaboration between Israeli pharmacists and American physicians. The company develops, manufactures, and markets a broad portfolio of prescription (Rx) medications, over-the-counter (OTC) products, and cosmetics across therapeutic areas including pain and inflammation, dermatology, cardiovascular, neurology and psychiatry, oncology, ophthalmology, gastroenterology, and endocrinology. Taro's core technical asset is vertical integration: its Chemistry Division in Haifa Bay synthesizes active pharmaceutical ingredients (APIs) across seven production lines, while its Pharma Division manufactures finished dosage forms through dedicated cells for dry-mix, granulation, liquids and foams, and semi-solids. R&D centers in Haifa, Brampton (Canada), and Hawthorne, NY focus on formulation, analytical development, and synthetic organic chemistry, supporting bioequivalence and clinical endpoint studies from pre-clinical through Phase IV.

The company sells its products through four wholly-owned regional subsidiaries — Taro USA, Taro Canada, Taro Israel, and Taro International — distributing Rx, OTC, and cosmetic products through pharmaceutical supply chains across North America, Central America, East Asia, Europe, Australia, and Israel. The revenue model is product sales across three categories (Rx, OTC, cosmetics) plus API manufacturing, with horizontal segmentation across therapeutic areas and persona-level targeting of healthcare professionals and end patients. Pricing is not publicly disclosed. Taro's competitive positioning rests on cGMP compliance certified by the FDA, UK MHRA, and Israeli Ministry of Health; IP-protected branded dermatological products; and leadership in US generic dermatology by 2016. The company was acquired by Sun Pharmaceuticals in 2010, completed an NYSE IPO in 2012 (the same year it surpassed $1B in gross sales), acquired Alchemee in 2022 to expand branded dermatology, and became a private wholly-owned subsidiary of Sun Pharma on June 24, 2024.

Taro Pharmaceutical Industries firmographics

Firmographics
Name
Taro Pharmaceutical Industries
Legal name
Taro Pharmaceutical Industries Ltd.
Website
https://taro.co.il
Company type
Private
Founded year
1950
Operating status
Operating
Headcount range
101–250 employees
Short description
Taro Pharmaceutical Industries is an Israel-based multinational generic and specialty pharmaceutical manufacturer developing, producing, and distributing Rx, OTC, and cosmetic products across multiple therapeutic areas through regional subsidiaries, now operating as a wholly-owned subsidiary of Sun Pharma since June 2024.
Ownership category
akta.pro rank

Taro Pharmaceutical Industries industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAL
Dermatology Specialty Pharmaceuticals

Keywords

  • Generic pharmaceuticals
  • Prescription medications
  • Topical dermatology
  • Active pharmaceutical ingredients
  • Finished dosage forms

Where Taro Pharmaceutical Industries is headquartered

Location

Headquarters

HQ city
Haifa
HQ country
Israel
HQ region
Middle East

Offices3 records

Markets served

Taro Pharmaceutical Industries business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Prescription (Rx) Pharmaceutical Products: Revenue from prescription-only medications developed and manufactured by Taro, covering therapeutic areas including pain, dermatology, digestive system, nervous system, cardiology, and more.
  2. Over-the-Counter (OTC) Products: Revenue from non-prescription products available directly to consumers, including topical formulations and other treatments.
  3. Cosmetic Products: Revenue from topical cosmetic products including creams, ointments, lotions, gels, and foams.
  4. Active Pharmaceutical Ingredients (API): Manufacturing and sale of active pharmaceutical ingredients used in medications for skin, cardiovascular, pain, and central nervous system conditions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Taro Pharmaceutical Industries product offering

Product offering

Core offering

Taro Pharmaceutical Industries develops, manufactures, and markets a broad portfolio of prescription (Rx), over-the-counter (OTC), and cosmetic pharmaceutical products across therapeutic areas including pain, dermatology, digestive system, nervous system, cardiology, oncology, and ophthalmology. The company is vertically integrated, synthesizing its own active pharmaceutical ingredients (APIs) and producing finished dosage forms in tablets, capsules, creams, ointments, gels, foams, solutions, and injectables. Taro operates R&D centers in Israel, Canada, and the United States, and is recognized as the leading generic dermatological company in the US market.

Product overview

Taro Pharmaceutical Industries is a multinational pharmaceutical company that develops, manufactures, and markets a broad portfolio of prescription (Rx) medications across multiple therapeutic areas including pain/inflammation, dermatology, cardiovascular, neurology/psychiatry, oncology, ophthalmology, and gastroenterology. The company offers products in various delivery forms including tablets, capsules, films, solutions, suspensions, creams, ointments, gels, foams, and injectables. Taro operates through two main divisions: the Pharma Division (manufacturing finished dosage forms including dry-mix, granulation, liquids/foams, and semi-solids production cells) and the Chemistry Division (manufacturing active pharmaceutical ingredients). R&D centers in Haifa (Israel), Brampton (Canada), and Hawthorne (NY, USA) focus on generic and branded products spanning oral solid-dose immediate and modified-release formulations, liquids, and dermatological topical formulations including creams, ointments, lotions, gels, and foams. The company is a leader in topical generic products and has developed extensive over-the-counter (OTC) offerings alongside its Rx portfolio.

Differentiator

Problem solved

Functional benefit

Products and services

  • Aquimod
  • Brexin
  • Capecitabine Taro
  • Cinacalcet Taro
  • Coumadin
  • Curatane
  • Dermacombin
  • Diprofol
  • Dorzolamide Timolol Taro
  • Dutasteride Taro
  • Entumin
  • Estelle 35
  • Etopan
  • Etopan XL
  • Etoricoxib Taro
  • Lataro
  • Lataro-Tim
  • Lozapine
  • Mercaptizol
  • Meroken
  • Nystatin Ready Mix
  • Odomzo
  • Otomycin
  • Oxacatin
  • Paracetamol Taro IV
  • Partane
  • Percocet
  • Perphenan
  • Pregabalin Taro
  • Profex
  • Promnix
  • Rokacet Plus
  • Sevelamer Taro
  • Sterocort
  • Taroclindin
  • Teril
  • Uramox
  • Zindaclin 1% Gel
  • Zoledronic Acid Taro
  • Active Pharmaceutical Ingredients (API)
  • Over-the-Counter (OTC) Pharmaceutical Products
  • Cosmetic Products

Companies that use Taro Pharmaceutical Industries

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Taro Pharmaceutical Industries technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Taro Pharmaceutical Industries partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor.

  • Sun Pharmaceutical USAminorOthersAffiliate company of Sun Pharma serving the US market.
  • Sun Pharmaceutical EuropeminorOthersAffiliate company of Sun Pharma serving the European market.
  • Chattem Chemicals Inc.minorOthersAffiliate company under the Sun Pharma umbrella.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Taro Pharmaceutical Industries competitors and assessment

Company assessment

Direct peers

  • Glenmark Pharmaceuticals: India-based global generic and specialty pharmaceutical company with a notable dermatology franchise. Comparable to Taro on integrated API-to-dosage manufacturing and dermatology emphasis.
  • Perrigo Company: US-based generic and OTC pharmaceutical manufacturer with strong consumer self-care and dermatology franchises. Comparable to Taro on the OTC + Rx + dermatology + multi-region distribution model.
  • Sandoz: Global generic pharmaceuticals business spun off from Novartis, offering broad Rx generics including dermatology, anti-infectives, and oncology. Comparable to Taro as a vertically capable generic manufacturer serving regulated markets.
  • Aurobindo Pharma: Indian-headquartered global generic pharmaceutical manufacturer with broad therapeutic coverage including dermatology. Comparable to Taro as a vertically integrated generic player supplying regulated markets.
  • Mayne Pharma: Specialty pharmaceutical company with significant generic dermatology and women's health franchises. Comparable to Taro on US-focused generic dermatology leadership and topical formulation capabilities.
  • Teva Pharmaceutical Industries: Israel-headquartered global generic pharmaceutical leader with a meaningful dermatology franchise. Taro is most directly comparable to Teva as both are Israeli generic pharma companies with multi-therapeutic portfolios and US market exposure.
  • Almirall: European dermatology-focused specialty pharmaceutical company. Directly comparable to Taro on the dermatology specialty positioning, with overlapping therapeutic focus on skin conditions.
  • Viatris: Global generics and specialty pharmaceutical company formed from Mylan/Upjohn merger. Comparable to Taro on multi-therapeutic generic portfolio, established dermatology position, and global supply chain scale.
  • Lupin Pharmaceuticals: Indian generic pharmaceutical major with US-focused operations across multiple therapeutic areas. Comparable to Taro on US generic commercialization, multi-therapeutic portfolio, and API integration.

Emerging players

  • Galderma: Dermatology-focused pharmaceutical and skincare company with strong prescription and consumer brands. Comparable to Taro on the dermatology focus, though more skewed toward branded aesthetics and skin care.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Taro Pharmaceutical Industries social profiles

Digital presence

Taro Pharmaceutical Industries compliance and trust

Trust signal

Compliance1 record

Taro Pharmaceutical Industries financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Taro Pharmaceutical Industries leadership team

Management profile

Number of profiles

Taro Pharmaceutical Industries subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Taro Pharmaceutical Industries funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Taro Pharmaceutical Industries M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Taro Pharmaceutical Industries

What does Taro Pharmaceutical Industries do?

Taro Pharmaceutical Industries develops, manufactures, and markets a broad portfolio of prescription (Rx), over-the-counter (OTC), and cosmetic pharmaceutical products across therapeutic areas including pain, dermatology, digestive system, nervous system, cardiology, oncology, and ophthalmology. The company is vertically integrated, synthesizing its own active pharmaceutical ingredients (APIs) and producing finished dosage forms in tablets, capsules, creams, ointments, gels, foams, solutions, and injectables. Taro operates R&D centers in Israel, Canada, and the United States, and is recognized as the leading generic dermatological company in the US market.

Is Taro Pharmaceutical Industries a public or private company?

Taro Pharmaceutical Industries is a private company. It is classified as corporate owned and is currently operating.

When was Taro Pharmaceutical Industries founded?

Taro Pharmaceutical Industries was founded in 1950. It employs 101 to 250 people.

Where is Taro Pharmaceutical Industries based?

Taro Pharmaceutical Industries is headquartered in Haifa, Israel, in the Middle East region.

How does Taro Pharmaceutical Industries make money?

Four revenue lines are on record. Prescription (Rx) Pharmaceutical Products are the primary driver. The others are over-the-Counter (OTC) Products, cosmetic Products and active Pharmaceutical Ingredients (API).

Who are Taro Pharmaceutical Industries's main competitors?

Direct peers on record are Glenmark Pharmaceuticals, Perrigo Company, Sandoz, Aurobindo Pharma, Mayne Pharma, Teva Pharmaceutical Industries, Almirall, Viatris and Lupin Pharmaceuticals. Galderma is listed as an emerging player.

Does Taro Pharmaceutical Industries have an API?

No public API is recorded for Taro Pharmaceutical Industries.

What industry is Taro Pharmaceutical Industries in?

Taro Pharmaceutical Industries's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIACAL, Dermatology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AInvestSun Pharma, units defendants in antitrust litigation in USSun Pharmaceutical Industries and its subsidiary Taro Pharmaceutical Industries have agreed to a $200 million settlement to resolve antitrust litigation brought by end purchasers in Pennsylvania. This agreement resolves claims stemming from allegations of a conspiracy to raise generic drug prices through market allocation, adding to previous settlements totaling over $160 million paid by the companies since 2022. The case, which involves 18 generic drugs and lawsuits from 40 states, continues to draw attention from other major corporations alleging similar price manipulation.PrtimesParonychia Treatment Market Driven by Rising Cases of Nail Infections Worldwide – PR TimesStellar Market Research published a market report indicating the global paronychia treatment market was valued at USD 631.05 million in 2024 and is projected to reach USD 1,150.84 million by 2032, growing at a CAGR of 7.8%, driven by rising nail infection cases and increased awareness of nail health. North America currently leads the market while Asia-Pacific is expected to register the fastest growth during the forecast period. The competitive landscape includes GlaxoSmithKline, Glenmark Generics, Teva Pharmaceutical Industries, Eli Lilly, Jonakayem Pharma Formulation, Fougera Pharmaceuticals, and Taro Pharmaceutical Industries, among others.openPR.comLeading Companies Fueling Growth and Innovation in the Actinic Keratosis Treatment MarketThe actinic keratosis treatment market is projected to grow to $4.94 billion by 2030 at a 7.7% CAGR, driven by new topical therapies, photodynamic treatments, and increased dermatology investments. Sun Pharmaceutical Industries Ltd. acquired Taro Pharmaceutical Industries Ltd. for $454 million in June 2024 to expand its dermatology and pediatrics portfolio. Additionally, Smith+Nephew PLC launched the RENASYS EDGE NPWT System in the United States in April 2024 for home-based wound care treatment.openPR.comCompetitive Landscape: Leading Companies and New Entrants in the Actinic Keratosis MarketThe actinic keratosis treatment market is projected to reach $11.06 billion by 2030, growing at a compound annual growth rate of 5.6%, driven by advances in photodynamic therapies, combination treatments, and expanded dermatology clinic networks. In June 2024, Sun Pharmaceutical Industries Limited completed a $454 million merger with Taro Pharmaceutical Industries Ltd., combining Sun Pharma's broad pharmaceutical portfolio with Taro's expertise in dermatology and topical treatments to enhance their competitive positioning. The market report also identifies key segments including topical treatments, surgical procedures, and photodynamic therapy across hospital pharmacies, drug stores, and dermatology clinics.Financial ExpressHow a Kolkata medicine trader built a $45 billion pharma empire from Rs 10,000Dilip Shanghvi founded Sun Pharmaceutical Industries in 1983 with Rs 10,000 borrowed from his father, building it into a $45 billion global pharma empire through strategic acquisitions including Ranbaxy Laboratories for $4 billion in 2015. Sun Pharma has grown to become India’s largest pharmaceutical company and the world’s fifth-largest specialty generic drug maker, with operations across more than 100 countries and a reported net profit margin of 18.62% for FY25. In June 2025, Sun Pharma announced a succession plan with Kirti Ganorkar taking over as Managing Director from September 1, 2025, while Shanghvi transitioned to Executive Chairman.GoodwinlawDelaware Supreme Court Affirms Dismissal of Books and Records Lawsuit Against Tech Company, Requiring Strict Compliance With Procedural RequirementsThe Delaware Supreme Court affirmed the dismissal of a books and records lawsuit against FloSports Inc. for procedural non-compliance and dismissed securities claims challenging a merger between Taro Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries Ltd. Additionally, various courts dismissed claims against BioAge Labs over clinical trial disclosures, Adobe over TAM statements, and Bristol-Myers Squibb over contingent value rights. Other cases involved partial success for cryptocurrency investors and securities fraud claims against NextEra Energy and Barclays.https://www.outlookbusiness.com/Sun Pharma Arm Recalls over 17K Units of Antifungal Shampoo in US: USFDA – Outlook BusinessTaro Pharmaceutical Industries, a unit of Sun Pharma, is recalling 17,664 units of Ciclopirox Shampoo in the US due to failed impurity/degradation specifications. The company initiated the Class II nationwide recall on December 9, a recall category that may cause temporary or medically reversible health consequences. Sun Pharma completed its merger with Taro last year valued at $347.73 million, making Taro a private company wholly owned by Sun Pharma.Financial ExpressSun Pharma recalls 17,000 units of antifungal shampoo in US over manufacturing issuesTaro Pharmaceutical Industries, a unit of Sun Pharmaceutical Industries, is recalling 17,664 units of Ciclopirox Shampoo in the US due to failed impurity and degradation specifications, according to the US Food and Drug Administration. The Class II recall, initiated on December 9, indicates temporary or medically reversible health consequences may occur from using the affected antifungal product. Taro, which focuses on dermatology products, became a wholly owned subsidiary of Sun Pharma after a merger completed last year valued at USD 347.73 million.The Times of IndiaSun Pharma arm recalls over 17,000 units of antifungal shampoo in US: USFDASun Pharma's subsidiary, Taro Pharmaceutical Industries, is recalling over 17,000 units of Ciclopirox Shampoo in the US due to failed impurity and degradation specifications. The Class II nationwide recall was initiated on December 9 following a USFDA enforcement report indicating potential for temporary or medically reversible health consequences. This event occurs within the context of Sun Pharma having fully merged with and acquired Taro for USD 347.73 million last year.RobertkinglawfirmProactiv Lawsuit [2026 Update]Multiple lawsuits have been filed against Taro Pharmaceutical Industries Ltd, the manufacturer of Proactiv acne treatment products, alleging the company marketed benzoyl peroxide-containing products despite knowing they could break down into benzene, a known carcinogen linked to blood cancers. An independent laboratory, Valisure, detected benzene levels up to 800 times the FDA’s allowable limit in these products and has submitted a Citizen’s Petition urging the FDA to issue an immediate recall, though no mandatory recall has been ordered to date.